Acorda CEO Ron Cohen Named BIO Chairman for 2015-2016 Term
June 15 2015 - 7:32AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that
President and Chief Executive Officer Ron Cohen, M.D, has been
elected as the Chair of the Biotechnology Industry Organization
(BIO) Board of Directors for the 2015-2016 term. He will also serve
as the Chairman of the Health Section Governing Board.
“The biotech industry is among the most innovative in the world,
developing life-changing medicines that improve our health,
agricultural advances that help us feed an expanding global
population, and cleaner, more efficient energy that allows us to
fuel our economy while preserving our environment,” said Dr. Cohen.
“It is a privilege to help BIO continue to advance our member
companies’ collective mission to contribute these extraordinary
advances to society.”
The BIO chair is a rotational position. Dr. Cohen will serve in
this role through June 2016, and is eligible for re-election for
another 1-year term. He previously served as Chair of the Emerging
Companies Section Governing Board and Vice Chair of the Health
Section Governing Board of BIO.
“Ron Cohen has been an active member of the Board for many years
and will bring tremendous passion and a wealth of industry
experience to help drive continued growth of BIO and the overall
industry,” said Jim Greenwood, BIO President and CEO. “I look
forward to working closely with Ron and our newly-constituted Board
of Directors in the years to come.”
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a
biotechnology company focused on developing therapies that restore
function and improve the lives of people with neurological
disorders.
Acorda markets three FDA-approved therapies, including
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a
treatment to improve walking in patients with multiple sclerosis
(MS), as demonstrated by an increase in walking speed. The Company
has one of the leading pipelines in the industry of novel
neurological therapies. Acorda is currently developing a number of
clinical and preclinical stage therapies. This pipeline addresses a
range of disorders including post-stroke walking deficits,
Parkinson’s disease, epilepsy, neuropathic pain, heart failure, MS
and spinal cord injury.
For more information, please visit the Company’s website
at: www.acorda.com.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or
prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including the ability to realize the
benefits anticipated from the Civitas transaction and to
successfully integrate Civitas' operations into our operations; our
ability to successfully market and sell Ampyra in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz, or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully
market CVT-301, Plumiaz, or any other products under development;
we may need to raise additional funds to finance our expanded
operations and may not be able to do so on acceptable terms; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence
on our collaboration partner Biogen in connection therewith;
competition; failure to protect our intellectual property, to
defend against the intellectual property claims of others or to
obtain third party intellectual property licenses needed for the
commercialization of our products; and, failure to comply with
regulatory requirements could result in adverse action by
regulatory agencies.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this release are made only as of the date hereof, and Acorda
disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150615005150/en/
Acorda TherapeuticsJeff Macdonald,
914-326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024